Index

A
ACC, 188
ADAM6, 31
AI. See Artificial intelligence
AKT, activation in cancer, 4
ALK
  immune checkpoint inhibitor therapy
    in non-small-cell lung cancer, 71–72
  mouse models of lung cancer, 102, 107–108, 112
  radiogenomics, 163
  rearrangements in lung cancer, 24, 64
ARID1A, 202
Artificial intelligence (AI)
  molecular pathology data interpretation, 41–42
    radiomics
      lung cancer applications
        early detection and screening, 153–156
        prognosis, 156–159
        radiogenomics, 160, 163–164
        treatment response, 157, 160–162
        overview, 150–153
ASCL1, 172, 221–222
ASNS. See Asparagine synthase
Asparagine synthase (ASNS), 187
AZD3965, 187

B
BAP1, 35
BCL9, 139
BEAS-2B, preclinical studies of lung cancer
  pathogenesis, 5–6
β-catenin, 138–139
BRAF
  alterations in lung cancer, 25
  mutations in early lung cancer, 2
BRD4, 203, 206
BRG1, 139, 202

C
CA125, 9
Cancer stem cell (CSC)
  antitumor immunity, 140–141
  clinical implications, 141–142
  drug persistence and signaling, 138–139
  heterogeneity, 137
  hypothesis in lung cancer, 134–136
  minimal residual disease role, 137–138
  niche, 138–139
  NOTCH signaling, 138
  origins of lung cancer, 136–137
  overview, 133–134
  Shh signaling, 139
  tumor heterogeneity role, 137–138
CBP, 204
CCAT1, 207
CD59, 5
CD200, 5
CDKN2A, 4
CEA, 9
Cell-free DNA (cfDNA)
  fragmentation profile, 40
  immune checkpoint inhibitor therapy response
    biomarker, 75–76
  methylation, 9
  relapse/recurrence detection, 12
cfDNA. See Cell-free DNA
Chromatin remodeling. See Epigenetics
Circular RNA, therapeutic targeting, 208
Circulating tumor cells (CTCs)
  characterization, 10
DNA. See also Cell-free DNA
  analysis, 39–40
  immune checkpoint inhibitor therapy
    response biomarker, 75–76
  isolation, 10
  non-small-cell lung cancer detection
    advanced cancer, 11
    early cancer, 10–11
  quantification, 39
  relapse/recurrence detection, 9–12
  small-cell lung cancer, 11–12
CKD7, 231
COLIA2, 31
COL3A1, 31
Computed tomography (CT). See also Radiomics
  early-stage non-small-cell lung cancer, 86
  locally advanced non-small-cell lung cancer, 89
  lung cancer screening, 7–8
  tumor metabolism imaging, 173–174
CREBBP, 221
Index

CSC. See Cancer stem cell
CT. See Computed tomography
CTCs. See Circulating tumor cells
CTLA-4
  immune checkpoint, 68–69
  immune checkpoint inhibitor therapy for non-small-cell lung cancer, 70–71, 73, 229
CYFRA 21-1, 9

D
DCCPS, 246
Deep learning (DL), molecular pathology data interpretation, 41–42
DL. See Deep learning
DNA methylation. See Epigenetics
DNMT1, 201
DNMT3a, 201
DNMT3b, 201
Durvalumab, 90

E
EGFR
  gene family mutations in lung cancer, 23–24, 71
  immune checkpoint inhibitor therapy in non-small-cell lung cancer, 71–72
  intertumor heterogeneity, 30, 35–37
  mouse models of lung cancer, 99, 107–108, 114, 118
  mutations in early lung cancer, 2
  radiogenomics, 163
EGFR
  metabolic changes in lung cancer alterations, 181–182
  therapeutic targeting, 183, 187
EML4, 24, 102
Epigenetics
  biomarkers in lung cancer, 209
  lung cancer studies, 27, 29
  targeting in lung cancer
    chromatin remodeling, 202
    circular RNA, 208
    DNA methylation, 201–202
    histone modifications
      acetylation, 204–205
      methylation, 203–204
      readers, 205–206
    long noncoding RNA, 207–208
    miRNA, 206–207, 209
    rationale, 199–201
    small nucleolar RNA, 208
ERBB2, 4, 24
EZH2, 204, 228

F
FADS2, 188
FHIT, 3
FOXO3, 208

G
Gene expression profiling (GEP), lung cancer studies, 26
Genetically engineered mice. See Mouse models
GENIE, 255
GEP. See Gene expression profiling
GLUT1, 172, 177
Gut microbiome, immune checkpoint inhibitor therapy response biomarker, 76–77

H
HBEC. See Human bronchial epithelium cell
HDAC. See Histone deacetylase
HDGE. See Hepatoma-derived growth factor
Hepatoma-derived growth factor (HDGF), 207
Histone deacetylase (HDAC)
  HDAC3, 205
  HDAC6, 206
  HDAC7, 204
  inhibitors, 29
Histone modifications. See Epigenetics
HLA-G, 5
HOTAIR, 207
HSAEC. See Human small airway epithelium cell
HTAN. See Human Tumor Atlas Network
Human bronchial epithelium cell (HBEC),
  preclinical studies of lung cancer pathogenesis, 6
Human small airway epithelium cell (HSAEC),
  preclinical studies of lung cancer pathogenesis, 6
Human Tumor Atlas Network (HTAN), 255

I
ICIs. See Immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs)
  protein targets. See specific proteins
  therapy for non-small-cell lung cancer advanced/unresectable disease, 72–73
  biomarkers of response
    circulating tumor DNA, 75–76
    gut microbiome, 76–77
    PDL-1, 74–75
    tumor mutational burden, 75
  checkpoint proteins, 68–69
  early-stage disease
adjuvant immunotherapy, 73
neoadjuvant immunotherapy, 73–74
metastasis
actionable molecular aberrations, 71–72
first-line therapy, 70–71
second-line therapy, 71
overview, 64
resistance mechanisms, 64
IMPDH, 172
INTERCEPT study, 41
Intertumor heterogeneity
adenosquamous carcinoma, 33
atypical carcinoid, 33
biomarkers, 30–31
bronchial mucoepidermoid carcinoma, 34
clonality, 35–37
large-cell lung carcinoma, 33
lung adenocarcinoma, 32
non-small-cell lung cancer, 31–32
overview, 29–30
pulmonary sarcomatoid carcinoma, 33–34
small-cell lung cancer
clinical significance, 224
floaters and stickers, 222
neuroendocrine versus non-neuroendocrine cells, 222
NOTCH expression, 222–223
overview, 34
subclonal mutations, 223–224
tumor-propagating cells, 223
vasculogenic mimicry, 223
squamous cell carcinoma, 33
typical carcinoid, 33
K
KDM3A, 203
KEAP1
metabolic changes in lung cancer alterations, 179–180
mouse models of lung cancer, 106
therapeutic targeting, 187
Knockout mice. See Mouse models
KRAS
alterations in lung cancer, 24–25
intertumor heterogeneity, 31
metabolic changes in lung cancer alterations, 178–179
mutations in early lung cancer, 2
radiogenomics, 163
LAG-3, immune checkpoint, 69
LCE. See Lung Cancer Explorer
LKB1, 4, 117
LKB1
metabolic changes in lung cancer alterations, 180–181
therapeutic targeting, 183, 187
IncRNA. See Long noncoding RNA
LOH. See Loss of heterozygosity
Long noncoding RNA (IncRNA), therapeutic targeting, 207–208
Loss of heterozygosity (LOH), early carcinogenesis, 3
LSD1, 204
LUAD. See Lung adenocarcinoma
Lung adenocarcinoma (LUAD)
intertumor heterogeneity, 32
metabolomics, 172
mouse models, 99, 102
Lung Cancer Explorer (LCE), 255–259
Lung squamous cell carcinoma (LUSC)
intertumor heterogeneity, 33
metabolomics, 172
mouse models, 102–103
LUSC. See Lung squamous cell carcinoma
Machine learning. See Artificial intelligence
Magnetic resonance imaging (MRI). See Radiomics
MALAT1, 207
MCP-1, tumor microenvironment, 66
MCT1, 172, 187
MET, alterations in lung cancer, 25
Metabolomics
cross talk in tumor microenvironment, 182–183
imaging tumor metabolism
computed tomography, 173–174
metabolic processes, 175
overview, 172–173
positron emission tomography
amino acid tracers, 176
glucose tracers, 174, 176
mitochondrial function, 176–177
nucleotide metabolism, 176
oxygen metabolism, 176
principles, 174
in situ tumor studies, 172–173
lung cancer histology studies, 172
molecular alterations and metabolic changes
EGFR, 181–182
KEAP1, 179–180
KRAS, 178–179
LKB1, 180–181
Metabolomics (Continued)
MYC, 182
NRD2, 179–180
overview, 177
p53, 177–178
PI3K, 179
therapeutic targeting of metabolism
amino acid metabolism, 187
glucose metabolism, 183, 187
lipid metabolism, 188
mitochondrial metabolism, 187–188
overview, 183–186
Metastasis, non-small-cell lung cancer
adoptive cell therapy with tumor-infiltrating
lymphocytes, 69–70
immune checkpoint inhibitor therapy
actionable molecular aberrations, 71–72
first-line therapy, 70–71
second-line therapy, 71
mouse models, 105
radiation therapy, 90–92
MicroRNA
lung cancer studies, 27–28
therapeutic targeting, 206–207, 209
Minimal residual disease (MRD)
cancer stem cell role, 137–138
cTDTNA as biomarker, 75–76
detection, 12
Mouse models
cancer immunology studies, 107–108
cell of origin studies, 104–105
genetically engineered mice prospects, 105–107
lung adenocarcinoma, 99, 102
lung squamous cell carcinoma, 102–103
metastasis, 105
overview of lung cancer models, 98–99
rationale, 97–98
resources, 258, 260, 263
small-cell lung cancer, 103
therapy studies for lung cancer
challenges with clinical translation, 118–119
drug resistance, 117–118
drug target discovery, 117
efficacy, 114, 117
mechanism of action, 114, 117
timeline of development for lung cancer, 100–102
tumor initiation and progression, 103–104
tumor progression, 105
xenograft studies
cell lines, 109–110
humanized mice, 113–114
lung differentiation and tumor pathogenesis
studies, 114
overview, 108–109
patient-derived xenografts, 111–113
small-cell lung cancer, 219–220
three-dimensional cultures and organoids, 109, 111
MRD. See Minimal residual disease
MRI. See Magnetic resonance imaging
MYC, 221
MYC, metabolic changes in lung cancer
alterations, 182
MYCL, 221
N
National Comprehensive Cancer Network (NCCN),
guidelines, 40–41, 250
National Lung Screening Trial (NLST), 7–8,
152–153, 156, 252
NCCN. See National Comprehensive Cancer Network
NCDB, 246
NELSON, 8
NEUROD1, 221–222
NF1, 106
NHBE cell. See Normal human bronchial
epithelium cell
NKX2-1, 4, 104
NLST. See National Lung Screening Trial
Nomogram, lung cancer tools, 250–251
Non-small-cell lung cancer (NSCLC)
adoptive cell therapy with tumor-infiltrating
lymphocytes for metastasis, 69–70
circulating tumor cells in detection
advanced cancer, 11
ever cancer, 10–11
immune checkpoint inhibitor therapy
advanced/unresectable disease, 72–73
biomarkers of response
circulating tumor DNA, 75–76
gut microbiome, 76–77
PDL-1, 74–75
tumor mutational burden, 75
checkpoint proteins, 68–69
ever-stage disease
adjuvant immunotherapy, 73
neoadjuvant immunotherapy, 73–74
metastasis
actionable molecular aberrations, 71–72
first-line therapy, 70–71
second-line therapy, 71
overview, 64
resistance mechanisms, 64
immune microenvironment, 64–67
Non-small-cell lung cancer (NSCLC) (Continued)

immunoediting and immunosuppression mechanisms, 67–68

inter-tumor heterogeneity, 31–32

metabolomics, 172

radiation therapy

early-stage cancer, 85–89

locally advanced cancer resectable, 89

unresectable, 89–90

stage IV and metastasis, 90–92

Normal human bronchial epithelium (NHBE) cell, preclinical studies of lung cancer pathogenesis, 5

NOTCH, 138, 222–224

NOTCH3, 138–139

NRD2, metabolic changes in lung cancer alterations, 179–180

NSCLC. See Non-small-cell lung cancer

NSF1, 109

NTRK, fusions in lung cancer, 25–26

p16INK4A, alterations in early lung cancer, 4

p53 gene. See TP53 metallocene changes in lung cancer alterations, 177–178

p300, 139

PARP, small-cell lung cancer treatment with inhibitors, 226–227

Patient-derived organotypic tumor spheroids (PDOTS), 111

PD-1, 229

PD-L1 circulating tumor cell expression, 11

expression and immunotherapy response, 37–38, 64, 74–75

immune checkpoint, 68

immune checkpoint inhibitor therapy for non-small-cell lung cancer, 70

immunosuppressive phenotype and immunotherapy, 230–232

VEGFR correlation, 24

PDOTS. See Patient-derived organotypic tumor spheroids

PET. See Positron emission tomography

PI3K, metabolic changes in lung cancer alterations, 179

PI3K/AKT/PTEN/mTOR pathway, up-regulation in lung cancer, 26

Positron emission tomography (PET). See also Radiomics

early-stage non-small-cell lung cancer, 86

locally advanced non-small-cell lung cancer, 89

tumor immunoresistance studies, 68

tumor metabolism imaging

amino acid tracers, 176

glucose tracers, 174, 176

mitochondrial function, 176–177

nucleotide metabolism, 176

oxygen metabolism, 176

principles, 174

POUF23, 221–222

Preclinical models. See Mouse models; specific cell lines

cell line resources, 258, 260

prospects for analysis and caveats, 260–263

PRMT, 203

Pro-SFTPB, 9

PTEN, 220–221

PTEN, 207

R

Radiation therapy. See Non-small-cell lung cancer

Radiomics

artificial intelligence, 151–153

limitations, 163, 165

lung cancer early detection and screening, 153–156

overview, 147–148

pipeline, 148–151

prognosis of lung cancer, 156–159

prospects, 165

radiogenomics, 160, 163–164

treatment response of lung cancer, 157, 160–162

RB1, 3, 103, 114, 222

RBL2, 220–221

Recurrence. See Screening, lung cancer

Registries, lung cancer, 246

Relapse

screening. See Screening, lung cancer

small-cell lung cancer chemoresistance, 228–229

RET, rearrangements in lung cancer, 25

ROS1 mouse models of lung cancer, 102, 112

rearrangements in lung cancer, 25

RTKN2, 31

Runx, 104

S

SAHA, 206

SCD, 188

SCLC. See Small-cell lung cancer

Screening, lung cancer

AKT activation, 4

© 2022 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

Screening, lung cancer (Continued)
atypical adenomatous hyperplasia abnormalities, 4–6
biological rationale, 6–7
chromosomal abnormalities, 3–4
molecular abnormalities in preneoplasia, 1–3
radiomics, 153–156
relapse/recurrence detection
cell-free DNA, 12
circulating tumor cells, 9–12
sputum and blood markers, 9
successes and challenges, 7–9
SEER, 246, 250
SGLT2, therapeutic targeting, 187
Shh, lung cancer stem cell signaling, 139
SLC1A5, 172
SLC7A11, 187
SLFN11, small-cell lung cancer chemoresistance role, 227–228
Small nucleolar RNA (snoRNA), therapeutic targeting, 208
Small-cell lung cancer (SCLC)
cell lines, 218–219, 222
chemoresistance
EZH2 role, 228
PARP inhibitors, 226–227
relapse, 228–229
SLFN11 role, 227–228
circulating tumor cells, 11–12
genomics and oncogenes, 220–222
immunosuppressive phenotype and immunotherapy, 229–231
intertumor heterogeneity, 34
intratumoral heterogeneity
clinical significance, 224
floaters and stickers, 222
neuroendocrine versus non-neuroendocrine cells, 222
NOTCH expression, 222–223
subclonal mutations, 223–224
tumor-propagating cells, 223
vasculogenic mimicry, 223
lineage plasticity and transdifferentiation, 225–226
metabolomics, 172
models, 218–220
mouse models, 103
origins, 224–225
overview, 217
SMARCA3, 203
SMARCA4, 202–203
snoRNA. See Small nucleolar RNA
SOX2
alterations in early lung cancer, 3
mouse models of lung cancer, 103
SPINK1, 31
Squamous cell carcinoma. See Lung squamous cell carcinoma
STK11, 64
STK11. See LKB1
T
TAK-288, 187
TAM. See Tumor-associated macrophage
TCGA. See The Cancer Genome Atlas
TCIA. See The Cancer Imaging Archive
Tertiary lymphoid structure (TLS), tumor microenvironment, 66–67
TGFB1, 4
TGFB3, 5
The Cancer Imaging Archive (TCIA), 152, 252
TIL. See Tumor-infiltrating lymphocyte
TIM-3, immune checkpoint, 69
TLS. See Tertiary lymphoid structure
TMB. See Tumor mutational burden
TNFRS14, 5
TP53
intertumor heterogeneity, 30
mouse models of lung cancer, 103, 105, 114, 117
mutations in early lung cancer, 2–3
small-cell lung cancer mutations, 222
Transgenic mice. See Mouse models
Tumor-infiltrating lymphocyte (TIL), adoptive cell therapy for non-small-cell lung cancer metastasis, 69–70
Tumor mutational burden (TMB)
causes of increase, 38
immune checkpoint inhibitor therapy response biomarker, 75
immunogenic response, 38–39
PD-L1 expression and immunotherapy response, 37–38
Tumor-associated macrophage (TAM), 66

V
VEGF, tumor microenvironment, 66
VEGFR, 24

X
Xenograft. See Mouse models

Y
YEATS2, 206